Metro (MRU) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
22 Apr, 2026Executive summary
Q2 sales reached CAD 5.1 billion, up 4.1% year-over-year, driven by new store openings, same-store sales growth, and a calendar shift.
Pharmacy segment maintained robust momentum, with same-store sales up 5.1% year-over-year.
Strong performance in discount banners and pharmacy, with private label and promotional activity supporting margins.
Online sales surged 19.8%, fueled by third-party marketplaces and expanded click-and-collect services.
Addressed operational challenges from a strike at the Laval produce distribution center, with contingency plans ensuring stores remain stocked.
Financial highlights
Gross margin was CAD 1.03 billion or 20.1% of sales, up from 20% last year, aided by productivity gains.
EBITDA reached CAD 508.6 million (9.9% of sales), up 10.3% year-over-year; adjusted EBITDA (excluding CAD 20.1 million gain) was CAD 488.5 million, up 6%.
Adjusted net earnings were CAD 236.5 million, up 4.4%; adjusted EPS was CAD 1.11, up 8.8%.
Net earnings for Q2 2026 were CAD 246.6 million, up 12.1% year-over-year; fully diluted EPS was CAD 1.16, up 17.2%.
Operating expenses were CAD 538.9 million, up 3.4% year-over-year, representing 10.5% of sales.
Outlook and guidance
Confident in continued growth through merchandising, private label, loyalty programs, and supply chain partnerships.
Strike in Québec/Laval expected to impact Q3 results; contingency plans in place to mitigate disruption.
Plans to open or convert about a dozen new stores in fiscal 2026, focusing on discount banners and efficiency gains.
Latest events from Metro
- Q2 sales up 5.5%, adjusted EPS up 12.1%, net earnings up 17.6%, supply chain investments ongoing.MRU
Q2 20254 Mar 2026 - Sales up 2.9%, adjusted EPS up 7.8%, online sales up 18.6%, and dividend raised 10.4%.MRU
Q1 20254 Mar 2026 - Sales up 3.5%, stable margins, but net earnings fell 14.6% amid automation costs.MRU
Q3 20244 Mar 2026 - Q4 saw higher margins, strong pharmacy and online sales growth, and a completed supply chain overhaul.MRU
Q4 20244 Mar 2026 - Q3 sales rose 3.3%, adjusted EPS up 12.6%, with strong pharmacy and discount banner growth.MRU
Q3 20254 Mar 2026 - Q4 sales and earnings rose despite supply chain disruptions, with a strong FY 2026 outlook.MRU
Q4 20254 Mar 2026 - Sales up 3.3%, adjusted EPS up 5.5%, net earnings down 12.8% on one-time costs; dividend up 10.1%.MRU
Q1 20264 Mar 2026 - Strong results, board re-elections, and strategic growth plans highlighted, with rising dividends.MRU
AGM 20259 Jan 2026